Pathological Significance and prognostic role of microvessel density, evaluated Using CD31, CD34, and CD105 in prostate cancer patients after radical prostatectomy with neoadjuvant therapy

Prostate

Volumn 75, Issue 1, 2015, Pages 84-91

  Miyata, Yasuyoshi ^a   Mitsunari, Kensuke ^a   Asai, Akihiro ^a   Takehara, Kosuke ^a   Mochizuki, Yasushi ^a   Sakai, Hideki ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

Angiogenesis; Biochemical recurrence; Neoadjuvant therapy; Thrombospondin 1; Vascular endothelial growth factor A

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CD31 ANTIGEN; CD34 ANTIGEN; ENDOGLIN; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; THROMBOSPONDIN 1; VASCULOTROPIN A; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; TUMOR MARKER;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CAPILLARY DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PREDICTIVE VALUE; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; SURVIVAL RATE; ADJUVANT THERAPY; METABOLISM; MICROVASCULATURE; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR RECURRENCE; VASCULARIZATION;

AGED; ANTIGENS, CD; ANTIGENS, CD31; ANTIGENS, CD34; BIOMARKERS, TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROVESSELS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, CELL SURFACE; THROMBOSPONDIN 1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84919398591     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22894     Document Type: Article

References (21)

1. Watson RB, Civantos F, Soloway MS. Positive surgical margins with radical prostatectomy, detailed pathological analysis and prognosis. Urology 1996; 48: 80-90.
2. Bettencourt MC, Bauer JJ, Sesterhenn IA, Connelly RR, Moul JW. CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. J Urol 1998; 160: 459-465.
3. Erbersdobler A, Isbarn H, Dix K, et al. Prognostic value of microvessel density in prostate cancer: A tissue microarray study.World J Urol 2010; 28: 687-692.
4. Miyata Y, Ohba K, Matsuo T, et al. Tumor-associated stromal cells expressing E-prostanoid 2 or 3 receptors in prostate cancer: Correlation with tumor aggressiveness and outcome by angiogenesis and lymphangiogenesis. Urology 2013; 81: 136-142.
5. Joseph IB, Nelson JB, Denmeade SR, et al. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res 1997; 3: 2507-2511.
6. Eisermann K, Broderick CJ, Bazarov A, Moazam MM, Fraizer GC. Androgen up-regulates vascular endothelial growth factor expression in prostate cancer cells via an Sp1 binding site. Mol Cancer 2013; 12: 7.
7. Colombel M, Filleur S, Fournier P, et al. Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate. Cancer Res 2005; 65: 300-308.
8. Joseph IB, Isaacs JT. Potentiation of the antiangiogenenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgenresponsive prostate cancers. Cancer Res 1997; 57: 1054-1057.
9. Stewart RJ, Panigrahy D, Flynn E, et al. Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: Evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J Urol 2001; 165: 688-693.
10. Miyata Y, Sagara Y, Watanabe S, et al. CD105 is a more appropriate marker for evaluating angiogenesis in urothelial cancer of the upper urinary tract than CD31 or CD34. Virchows Arch 2013; 463: 673-679.
11. Miyata Y, Koga S, Takehara K, et al. Expression of thrombospondin- derived 4N1K peptide-containing proteins in renal cell carcinoma tissues is associated with a decrease in tumor growth and angiogenesis. Clin Cancer Res 2003; 9: 1734-1740.
12. Aslan G, Cimen S, Yorukoglu K, et al. Vascular endothelia growth factor expression in untreated and androgen-deprived patients with prostate cancer. Pathol Res Pract 2005; 201: 593-598.
13. Kumar P, Wang JM, Bernabeu C. CD105 and angiogenesis. J Pathol 1996; 178: 363-366.
14. Tanaka F, Otake Y, Yanagihara K, et al. Evaluation of angiogenesis in non-small cell lung cancer: Comparison between anti- CD34 antibody and anti-CD105 antibody. Clin Cancer Res 2001; 7: 3410-3415.
15. Rubatt JM, Darcy KM, Hutson A, et al. Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A gynecologic oncology group study. Gynecol Oncol 2009; 112: 469-474.
16. Fitchev PP, Wcislak SM, Lee C, et al. Thrombospondin-1 regulates the normal prostate in vivo through angiogenesis and TGF-b action. Lab Invest 2010; 90: 1078-1090.
17. Matsushima H, Goto T, Hosaka Y, et al. Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation. Cancer 1999; 85: 1822-1827.
18. Cheng L, Zhang S, Sweeney CJ, et al. Androgen withdrawal inhibits tumor growth and is associated with decrease in angiogenesis and VEGF expression in androgen-independent CWR22Rv1 human prostate cancer model. Anticancer Res 2004; 24: 2135-2140.
19. Sato F, Furuhara H, Basilion JP. Effects of hormone deprivation and 2-methoxyestradiol combination therapy on hormone-dependent prostate cancer in vivo. Neoplasia 2005; 7: 838-846.
20. Tomić TT, Gustavsson H, Wang W, et al. Castration resistant prostate cancer is associated with increased blood vessel stabilization and elevated levels of VEGF and Ang-2. Prostate 2012; 72: 705-712.
21. Ryan CJ, Smith A, LAL P, et al. Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: An early predictor of relapse or incomplete androgen suppression. Urology 2006; 68: 834-839.